FLT3-harboring VRP (VRP-FLT3) vs control VRP (VRP-Ctrl, vector alone) were administered by footpad injection as therapeutic vaccines on days 4 and 18 after tumor challenge. This evidence concerns the gene FLT3 and neoplasm.